MHRA: Updated Parenteral Nutrition Filter Guidance Mandates Filter Use

• The MHRA has issued updated guidance mandating the use of filters for all parenteral nutrition administration to enhance patient safety.
• All parenteral nutrition solutions must be administered through a filter no larger than 1.2μm, with 0.2μm filters recommended for aqueous solutions where available.
• This directive follows a Regulation 28 Prevention of Future Deaths report and aims to resolve inconsistencies in existing product guidance.
• The British Pharmaceutical Nutrition Group's 2025 position statement, supporting routine filter use, has been endorsed by several key professional bodies.
• The MHRA has instructed all parenteral nutrition product providers to align their product information with these new filter requirements to prevent adverse incidents like embolisms and particulate deposition.

The Medicines and Healthcare products Regulatory Agency has now formally requested that all providers of parenteral nutrition products update their product information to incorporate these essential filter requirements.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance emphasizing the critical importance of using filters during the administration of parenteral nutrition (PN) for patients across all care settings. This directive follows a review that identified inconsistencies in existing recommendations, contributing to variations in clinical practice. The MHRA's updated MHRA parenteral nutrition filter guidance specifically advises healthcare professionals to employ either integrated or add-on filters when administering these solutions.

The agency's intervention stems from a concerning history of adverse incidents, including a fatal embolism, directly linked to the administration of parenteral nutrition without an appropriate filter. To mitigate such risks, the guidance now mandates that all parenteral nutrition solutions must be administered via a filter with a pore size no larger than 1.2μm. Furthermore, for aqueous or lipid-free parenteral nutrition solutions, the use of a 0.2μm filter is recommended as good practice, where such filters are available.

The MHRA's comprehensive review of filter use guidance was prompted by a Regulation 28 Prevention of Future Deaths report, which highlighted the urgent need for clearer, standardized protocols. Parenteral nutrition, defined as the intravenous provision of nutrients, is primarily utilized when the standard gastrointestinal tract route for nutrition is unfeasible. These solutions are complex, typically comprising a combination of amino acids, lipid emulsion, glucose, vitamins, trace elements, electrolytes, and water.

Administering parenteral nutrition is considered a high-risk therapy due to several inherent challenges, including concerns about physicochemical stability, the potential for microbial contamination, and the risk of catheter-related sepsis, all compounded by the necessity for intensive monitoring. While parenteral nutrition products are regulated as medicinal products, they can also be supplied as unlicensed, bespoke variants known as 'specials' to address unmet patient needs, or prepared in pharmacies exempt from manufacturing license requirements. The administration sets for PN may feature integrated in-line filters, but separate add-on filters are also a viable option.

A key finding of the MHRA's review was that guidance provided by parenteral nutrition product providers often lacked consistency or failed to align with the recommendations from the British Pharmaceutical Nutrition Group (BPNG). The BPNG's 2025 position statement strongly advocates for the routine use of filters in all parenteral nutrition administration, specifically recommending a 1.2μm filter for all PN and a 0.2μm filter for aqueous (lipid-free) nutrition as best practice, alongside the inclusion of minimum filtration requirements in product literature.

This position has garnered significant endorsement from leading professional bodies, including the British Association of Parenteral and Enteral Nutrition, the Neonatal and Paediatric Pharmacy Group, and the National Nurses Nutrition Group. Consequently, the Medicines and Healthcare products Regulatory Agency has now formally requested that all providers of parenteral nutrition products update their product information to incorporate these essential filter requirements, ensuring alignment with the updated MHRA parenteral nutrition filter guidance and promoting consistent parenteral nutrition filter requirements UK-wide.

The fundamental role of filters in parenteral nutrition administration is to safeguard patients from two primary hazards: air infusion and particulate matter. Air infusion can lead to a dangerous air embolus, a condition that has been associated with severe adverse outcomes. Particulate matter, on the other hand, can originate from various sources, including the infusion systems themselves, components within the parenteral nutrition solution, manual connections of device components, manipulations during preparation, or precipitates resulting from physicochemical interactions between nutrient components or co-administered medications.

Without effective filtration, these particles pose a significant risk, as they can be deposited in the body's microvasculature, potentially leading to serious complications. The updated guidance, therefore, reinforces the critical need for robust filtration protocols to enhance patient safety and prevent adverse incidents during PN administration, underscoring the importance of adhering to the specified 1.2μm filter PN administration standard.

Lawyers advising pharmaceutical companies or healthcare providers must ensure their clients are aware of and comply with the MHRA's updated guidance on parenteral nutrition filter use, particularly regarding product information alignment and adherence to specific pore size recommendations, to mitigate risks of adverse incidents, potential liability arising from patient harm, and regulatory non-compliance.

Source: Reporting based on recent MHRA guidance.